Drug intelligence / Profile preview

Araclon Parkinson's disease program

Development stage: Preclinical
Lead developer: Araclon Biotech

Overview

This unnamed preclinical research program, developed by Araclon Biotech (a subsidiary of Grifols) in collaboration with the Spanish National Research Council (CSIC), targets Parkinson's disease. The therapeutic approach focuses on modulating and promoting the dopaminergic differentiation pathway of original brain cells to restore dopaminergic neuron populations. Currently in the animal concept-testing and preclinical stage, the project is supported by funding from the Spanish Ministry of Economy and Competitiveness (grant RTC-2015-3439-1). Araclon Biotech holds an exclusive license to the first patent generated from this project, which represents an exploratory effort into regenerative medicine for Parkinson's disease.

Other names: DOPADIFF

Beyond the preview

Go deeper on Araclon Parkinson's disease program.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Araclon Parkinson's disease program.

Explore the full profile